Jorge Betancor, MD
Interventional Cardiology · Seattle, WANPI 1114241619
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,706 of the $15,181 with a category attached, or 77.1%. 33 manufacturers reported payments, led by Abbott at 25.8% of the total. Reporting peaked in 2022 at $4,035 and has fallen 54.3% since, to $1,845 in 2025.
Across 199 payments — averaging $76.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Edwards Lifesciences$3K
- Medtronic$2K
- Abiomed$1K
- Boston Scientific$1K
- Bard Peripheral Vascular, Inc.$361
- plus $3K from 27 others
What the payments were for
- Travel & lodging$3,47323%
- Food & beverage$11,70677%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 34 | $3,922 |
| Edwards Lifesciences | 34 | $2,914 |
| Medtronic(2 entities) | 27 | $2,460 |
| Abiomed | 13 | $1,274 |
| Boston Scientific | 15 | $1,173 |
| Bard Peripheral Vascular, Inc. | 4 | $361 |
| Inari Medical, Inc. | 4 | $341 |
| Cardiva Medical, Inc. | 4 | $282 |
| AstraZeneca | 6 | $205 |
| Penumbra, Inc. | 2 | $200 |
| Johnson & Johnson | 5 | $194 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $186 |
| Shockwave Medical, Inc | 2 | $167 |
| Pfizer | 3 | $154 |
| Esperion Therapeutics, Inc. | 7 | $144 |
| Heartflow, Inc. | 1 | $133 |
| Stryker | 1 | $133 |
| E.r. Squibb & Sons, L.L.C. | 1 | $123 |
| Boehringer Ingelheim | 1 | $110 |
| Actelion Pharmaceuticals US, Inc. | 3 | $94 |
| Cook Medical LLC | 2 | $91 |
| Philips North America LLC | 1 | $84 |
| Novartis | 4 | $81 |
| United Therapeutics Corporation | 2 | $69 |
| Astellas Pharma US Inc | 4 | $68 |
| Impulse Dynamics (USA) Inc. | 2 | $40 |
| AbbVie | 2 | $40 |
| Amgen | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| Cvrx, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$1,717
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,102
- Impella$898
- MyCareLink$684
- TRICLIP$531
- Micra$391
- SAPIEN 3 Ultra RESILIA$313
- COREVALVE EVOLUT R$284
- CareLink Express$171
- AVVIGO Guidance System$170
- SUPERA$168
- Mitra Clip system$166
- GENERAL VASCULAR ACCESS$162
- FLOWTRIEVER CATHETER, S$153
- CT THROMBECTOMY SYSTEM KIT$153
- STINGRAY$149
- Vascular Lithotripsy$148
- WATCHMAN Access System$142
- Indigo System$140
- Trifecta GT Tissue Heart Valve$139
How this compares
$15,181 in reported general payments places this provider in the 75th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 34 | $41,314 |
| EliquisApixaban | 25 | $28,265 |
| JardianceEmpagliflozin | 27 | $23,840 |
| OzempicSemaglutide | 20 | $20,742 |
| BrilintaTicagrelor | 24 | $12,575 |
| Rosuvastatin Calcium | 99 | $1,960 |
| Atorvastatin Calcium | 128 | $1,653 |
| Metoprolol Succinate | 114 | $1,120 |
| ClopidogrelClopidogrel Bisulfate | 82 | $958 |
| Ezetimibe | 36 | $904 |
| Losartan Potassium | 33 | $315 |
| Pantoprazole Sodium | 26 | $288 |
| Spironolactone | 40 | $271 |
| Furosemide | 73 | $251 |
| Amlodipine Besylate | 27 | $227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $81 | $41,31434 claims |
| PfizerEliquis | $154 | $28,26525 claims |
| Boehringer IngelheimJardiance | $110 | $23,84027 claims |
| Novo NordiskOzempic | $16 | $20,74220 claims |
| AstraZenecaBrilinta | $205 | $12,57524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 125 interventional cardiology providers in Washington.
Other interventional cardiology in Seattle
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Danny DvirSeattle$374K
- James McCabeSeattle$289K
- Christopher BrownSeattle$266K
- Lorenzo AzzaliniSeattle$233K
- Sidakpal PanaichSeattle$214K
- Christine ChungSeattle$210K
- Sameer GafoorSeattle$80K
- Ravi HiraSeattle$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.